Does aceruloplasminemia modulate iron phenotype in thalassemia intermedia?

Blood Cells Mol Dis. 2016 Mar:57:112-4. doi: 10.1016/j.bcmd.2015.12.011. Epub 2015 Dec 30.

Authors

Sara Pelucchi¹, Irene Pelloni², Cristina Arosio³, Raffaella Mariani², Alberto Piperno⁴

Affiliations

¹ School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
² Centre for Diagnosis and Treatment of Hemochromatosis, S. Gerardo Hospital, Monza, Italy.
³ Consortium for Human Molecular Genetics, Monza, Italy.
⁴ School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; Centre for Diagnosis and Treatment of Hemochromatosis, S. Gerardo Hospital, Monza, Italy; Consortium for Human Molecular Genetics, Monza, Italy. Electronic address: [email protected].

PMID: 26777753
DOI: 10.1016/j.bcmd.2015.12.011

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Base Sequence
Ceruloplasmin / deficiency*
Ceruloplasmin / genetics*
Deferoxamine / therapeutic use
Exons
Gene Expression
Humans
Introns
Iron / metabolism
Iron Chelating Agents / therapeutic use
Iron Metabolism Disorders / complications
Iron Metabolism Disorders / diagnosis
Iron Metabolism Disorders / drug therapy
Iron Metabolism Disorders / genetics*
Iron Overload / complications
Iron Overload / diagnosis
Iron Overload / drug therapy
Iron Overload / genetics*
Male
Middle Aged
Molecular Sequence Data
Mutation
Neurodegenerative Diseases / complications
Neurodegenerative Diseases / diagnosis
Neurodegenerative Diseases / drug therapy
Neurodegenerative Diseases / genetics*
Phenotype
Transferrin / genetics
alpha-Globins / genetics*
beta-Globins / genetics*
beta-Thalassemia / complications
beta-Thalassemia / diagnosis
beta-Thalassemia / drug therapy
beta-Thalassemia / genetics*

Substances

Iron Chelating Agents
Transferrin
alpha-Globins
beta-Globins
Iron
Ceruloplasmin
Deferoxamine

Supplementary concepts

Familial apoceruloplasmin deficiency